Background Lemierre syndrome is characterized by head/neck vein thrombosis and septic
embolism usually complicating an acute oropharyngeal bacterial infection in adolescents …

2.1. 1. Epidemiology and burden of the disease. The annual incidence of first episode of
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …

The anticoagulation field is experiencing a renaissance that began with regulatory approval
of the direct thrombin inhibitor dabigatran, a direct oral anticoagulant (DOAC), in 2010. The …

Background Treatment of venous thromboembolism in children is based on data obtained in
adults with little direct documentation of its efficacy and safety in children. The aim of our …

Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in
randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard …

Background Recently, the randomized EINSTEIN‐Jr study showed similar efficacy and
safety for rivaroxaban and standard anticoagulation for treatment of pediatric venous …

Anticoagulant treatment of pediatric central venous catheter–related venous
thromboembolism (CVC-VTE) has not been specifically evaluated. In EINSTEIN-Jr, 500 …

Venous thromboembolism (VTE) in children is a rare occurrence, although in recent
decades we have seen an increase due to several factors, such as the rise in survival of …

The non–vitamin K antagonist oral anticoagulant rivaroxaban is used in several
thromboembolic disorders. Rivaroxaban is eliminated via both metabolic degradation and …

ABSTRACT Background Direct oral anticoagulants (DOACs) represent a cornerstone of
venous thromboembolism (VTE) treatment in adults. Recently, randomized controlled trials …